In Brief: SmithKline Beecham Clinical Labs/Hyseq
This article was originally published in The Gray Sheet
Executive Summary
SmithKline Beecham Clinical Labs/Hyseq: Enter agreement whereby SBCL will license the "Format-1 A" process of Hyseq's sequencing-by-hybridization DNA diagnostic technology, which enables the detection of normal and mutated genes. The license is non-exclusive except for tests Hyseq develops specifically for SBCL. SBCL says it will use the Hyseq technology to develop new diagnostics, including tests for "previously unknown" genetic mutations...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.